Gastro Medical News about Capecitabine

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group
British Journal of Cancer, 09/16/09

Garcia–Alfonso P et al. – Combination chemotherapy is standard treatment for metastatic colorectal cancer (MCRC). Capecitabine and irinotecan, given every 2 weeks, as first–line treatment of MCRC is an active regimen with a manageable toxicity profile, even in older patients.

<< Previous
Frequency and Influence of Hemochromatosis Gene Mutations in...

Next >>
Biomarkers for noninvasive biochemical diagnosis of nonalcoholic...